Press coverage about Axovant Sciences (NASDAQ:AXON) has trended somewhat positive on Wednesday, according to Accern. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Axovant Sciences earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.4740968862789 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

Axovant Sciences (AXON) traded up $0.02 during trading hours on Wednesday, reaching $2.11. The company had a trading volume of 2,059,900 shares, compared to its average volume of 3,794,930. The firm has a market cap of $224.04 and a PE ratio of -0.91. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.94 and a current ratio of 5.94. Axovant Sciences has a 1-year low of $2.02 and a 1-year high of $27.98.

Axovant Sciences (NASDAQ:AXON) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.09). equities research analysts predict that Axovant Sciences will post -2.17 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on AXON shares. BidaskClub raised Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 23rd. Chardan Capital reaffirmed a “sell” rating and issued a $3.00 price objective on shares of Axovant Sciences in a research report on Saturday, September 23rd. Oppenheimer reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Axovant Sciences in a research report on Monday, September 25th. Robert W. Baird cut Axovant Sciences from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $29.00 to $6.00 in a research report on Tuesday, September 26th. Finally, UBS Group cut Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $14.14.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-axovant-sciences-axon-stock-price/1810993.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Insider Buying and Selling by Quarter for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.